Sutro Biopharma
STRO
100 hedge funds and large institutions have $546M invested in Sutro Biopharma in 2026 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 17 closing their positions.
135% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 17
52% more capital invested
Capital invested by funds: $358M → $546M (+$187M)
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
28% more funds holding
Funds holding: 78 → 100 (+22)
12.63% more ownership
Funds ownership: 86.83% → 99.46% (+13%)
0% more call options, than puts
Call options by funds: $372K | Put options by funds: $372K
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$27.7M |
| 2 |
PA
Perceptive Advisors
New York
|
+$18.4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$7.92M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.65M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$7.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$17.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$14.2M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$5.75M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.98M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.75M |
STRO Hedge Fund Activity: Q2 2026 in Review
100 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q2 2026, worth a combined $546M — up 52% from $358M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new STRO positions and 17 closed out — a net gain of 23 holders — while 24 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $27.7M. The largest seller was RA Capital Management, exiting entirely with an estimated $17.8M sold.
- 100 institutional investors held Sutro Biopharma (STRO) as of Q2 2026, up from 78 in Q1 2026.
- Funds reported $546M of Sutro Biopharma stock for Q2 2026, up 52% quarter-over-quarter.
- 40 funds opened new Sutro Biopharma positions in Q2 2026 and 17 closed out, a net change of +23 holders.
- The largest Sutro Biopharma buyer in Q2 2026 was BlackRock, an estimated $27.7M added.
- The largest Sutro Biopharma seller in Q2 2026 was RA Capital Management, an estimated $17.8M sold.
Based on aggregated 13F filings for Q2 2026.